^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MEDI0680

    i
    Other names: MEDI0680, AMP-514, AMP 514, MED0680
    Company:
    AstraZeneca
    Drug class:
    PD1 inhibitor
    Related drugs:
    over2years
    A Randomized Ph2 Study of MEDI0680 in Combination With Durvalumab vs. Nivolumab Monotherapy in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma. (PubMed, Clin Cancer Res)
    MEDI0680 combined with durvalumab was safe and tolerable; however, it did not improve efficacy versus nivolumab monotherapy.
    P2 data • Journal • Combination therapy • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden)
    |
    Opdivo (nivolumab) • Imfinzi (durvalumab) • MEDI0680
    over4years
    Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies. (PubMed, J Immunother Cancer)
    MEDI0680 induced peripheral T-cell proliferation and increased plasma IFNγ and associated chemokines regardless of clinical response. CD8+ T-cell tumor infiltration and tumoral gene expression of IFNG, CD8A, CXCL9, and granzyme K (GZMK) were also increased following MEDI0680 administration.
    Clinical • P1 data • Journal • PD(L)-1 Biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CXCL9 (Chemokine (C-X-C motif) ligand 9)
    |
    CD8 expression • IFNG expression
    |
    MEDI0680
    over4years
    Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer. (PubMed, Int Immunopharmacol)
    This review aims to summarize the recent advances and challenges of ICIs including nivolumab, pembrolizumab, PF-06801591, MEDI0680, atezolizumab, durvalumab, ipilimumab, tremelimumab, and other new PD-1/PD-L1 and CTLA-4 inhibitors in immunotherapy of NSCLC. We hope to provide a better understanding of the mechanisms, clinical research progress and future research directions of NSCLC immunotherapy.
    Review • Journal • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab) • sasanlimab (PF-06801591) • MEDI0680